Table 1. Baseline characteristics of metastatic colorectal cancer patients.
| Patients’ characteristics | SIRT | SIRT-C |
|---|---|---|
| Number of patients | 14 | 13 |
| Mean age | 62 | 63 |
| Sex | ||
| Female | 4 | 5 |
| Male | 10 | 8 |
| Primary lesion | ||
| Rectal | 3 | 1 |
| Colon | 11 | 12 |
| Extrahepatic disease | ||
| None | 3 | 3 |
| Low | 4 | 3 |
| High | 7 | 7 |
| RAS status | ||
| Mutated | 4 | 10 |
| Wild Type | 10 | 3 |
| Median line of prior therapies | 3 | 2 |
| Concurrent chemotherapy with SIR-Spheres® | 0 | |
| 5-FU | 5 | |
| Capecitabine | 3 | |
| FOLFOX | 4 | |
| Irinotecan | 1 |
SIRT, SIR-Spheres® alone; SIRT-C, SIR-Spheres® with concurrent chemotherapy; 5-FU, 5-fluorouracil; FOLFOX, 5-FU, leucovorin, and oxaliplatin; FOLFIRI, 5-FU, leucovorin, and irinotecan.